logo.png
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
November 29, 2024 08:05 ET | Silo Pharma, Inc.
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Green and Gray.png
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
November 07, 2024 07:05 ET | Dogwood Therapeutics, Inc.
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
Green and Gray.png
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
October 31, 2024 09:15 ET | Dogwood Therapeutics, Inc.
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today...
Green and Gray.png
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 07, 2024 07:05 ET | Virios Therapeutics
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms
September 09, 2024 07:00 ET | Tilray Brands, Inc.
LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the...
Virios Logo Blue.jpg
Virios Therapeutics Announces Second Quarter 2024 Financial Results
August 08, 2024 09:15 ET | Virios Therapeutics
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman...
Virios Logo Blue.jpg
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024 09:41 ET | Virios Therapeutics
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
finacialnews-logo-final-01 (2).png
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024 08:30 ET | FN Media Group LLC
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher...
Virios Logo Blue.jpg
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
July 23, 2024 09:15 ET | Virios Therapeutics
- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients,...
Aviv-Clinic Logo.png
Aviv Clinics Spotlights New Study Using Hyperbaric Oxygen Therapy for Adults Suffering from Fibromyalgia Related to Childhood Sexual Abuse
May 28, 2024 09:00 ET | Aviv Clinics
ORLANDO, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the world’s most advanced brain treatment centers, shared the results of a new study which shows hyperbaric oxygen therapy (HBOT)...